Amgen's TEZSPIRE Shows Positive Phase 3 Results in Eosinophilic Esophagitis
Event summary
- Amgen's TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in a Phase 3 trial for eosinophilic esophagitis (EoE).
- The trial met both co-primary endpoints: histologic remission and improvement in dysphagia symptoms, with results sustained through week 52.
- TEZSPIRE is already approved for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
- The Phase 3 CROSSING trial involved 368 patients aged 12-80 years with symptomatic and uncontrolled EoE.
- Full results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.
The big picture
Amgen's positive Phase 3 results for TEZSPIRE in EoE represent a strategic expansion into a third epithelial-driven inflammatory disease, following approvals in severe asthma and CRSwNP. The success of TEZSPIRE underscores the potential of targeting thymic stromal lymphopoietin (TSLP) as a key inflammatory mediator. This positions Amgen to capture a significant share of the growing market for treatments addressing chronic inflammatory conditions, particularly as the prevalence of EoE continues to rise.
What we're watching
- Regulatory Approval
- The pace at which regulatory authorities review and approve TEZSPIRE for EoE will determine its market entry timing and competitive positioning.
- Market Expansion
- Whether Amgen can leverage TEZSPIRE's success in EoE to expand its market presence in other epithelial-driven inflammatory diseases.
- Competitive Dynamics
- How existing treatments for EoE will respond to TEZSPIRE's entry, particularly given the high unmet need in this indication.